Michael J. Weyant, MD
Dr. Michael Weyant is a board-certified thoracic surgeon and system-wide director of the thoracic surgery program at Inova Health in Falls Church, Virginia. Dr. Weyant’s clinical practice is in treating patients with lung cancer and other thoracic malignancies and diseases including malignant pleural mesothelioma. His particular skill is in the use of robotic minimally invasive surgical techniques including lung-sparing surgery.[1]
Education and Career
Dr. Weyant earned his medical degree at Mount Sinai School of Medicine, in New York. He completed his internship and residency in General Surgery at New York-Presbyterian Weill Cornell Medical Center and then completed a fellowship in Thoracic Surgery at Memorial Sloan Kettering Cancer Center.
Following completion of his medical education and training, Dr. Weyant was a thoracic surgeon and professor of surgery at the University of Colorado, where he practiced for more than 15 years.[1]
Professional Activities and Memberships
Dr. Weyant is active in several professional medical societies, including:[1]
- Member, American Association for Thoracic Surgery
- Member, Society of Thoracic Surgeons
- Fellow, American College of Chest Physicians
- Fellow, American College of Surgeons
- Member, International Association for the Study of Lung Cancer
- Member, Society for Surgery of the Alimentary Tract
- Member, General Thoracic Surgical Club
- Member, Western Thoracic Surgical Association
- Member, American Association for Cancer Research
Research
Dr. Weyant’s research interests focus on the benefits of early screening for lung cancer and improving outcomes for patients undergoing thoracic surgeries.
His research includes:[1]
Notch1 promotes the pro-osteogenic response of human aortic valve interstitial cells via modulation of ERK1/2 and nuclear factor-κB activation. Zeng Q, Song R, Ao L, Weyant MJ, Lee J, Xu D, Fullerton DA, Meng X.Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1580-90. doi: 10.1161/ATVBAHA.112.300912. Epub 2013 May 2.PMID: 23640488
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. Yu JA, Mauchley D, Li H, Meng X, Nemenoff RA, Fullerton DA, Weyant MJ.J Thorac Cardiovasc Surg. 2012 Nov;144(5):1185-91. Doi: 10.1016/j.jtcvs.2012.08.003.PMID: 23079010
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells. Yu JA, Li H, Meng X, Fullerton DA, Nemenoff RA, Mitchell JD, Weyant MJ.J Thorac Cardiovasc Surg. 2012 Dec;144(6):1479-85. Doi: 10.1016/j.jtcvs.2012.08.064. Epub 2012 Sep 29.PMID: 23026567
Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells. Yu JA, Kalatardi S, Dohse J, Sadaria MR, Meng X, Fullerton DA, Weyant MJ.Anticancer Res. 2012 Sep;32(9):3601-7.PMID: 22993297
